Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233988 | 0.80 | MMP2 (0.48) | MMP2MMP9MMP8PSMB5ALDH1A1 | |
| SCHEMBL2295176 | 0.77 | PSMB5 (0.47) | MMP2MMP9MMP8KMT2APSMB5 | |
| Hydrochloric Acid SCHEMBL2297582 | 0.76 | PSMB5 (0.47) | MMP2MMP9MMP8KMT2APSMB5 | |
| SCHEMBL1406331 | 0.76 | MMP2 (0.41) | MMP2MMP9MMP8RENPSMB5 | |
| Alanine SCHEMBL671385 | 0.75 | PSMB5 (0.46) | MMP2MMP9MMP8KMT2APSMB5 | |
| SCHEMBL901425 | 0.75 | ALDH1A1 (0.38) | MMP2MMP9MMP8KMT2APSMB5 | |
| Leucine SCHEMBL3812226 | 0.73 | MMP2 (0.48) | MMP2MMP9MMP8PSMB5ALDH1A1 | |
| Leucine SCHEMBL2297615 | 0.73 | MMP2 (0.49) | MMP2MMP9MMP8RENPSMB5 | |
| Leucine SCHEMBL1406254 | 0.72 | MMP2 (0.50) | MMP2MMP9MMP8ALDH1A1KDM4E | |
| SCHEMBL10491053 | 0.71 | KMT2A (0.59) | MMP8KMT2ANPSR1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953013-B2 | Biomarkers of response to NAE inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10662477-B2 | Biomarkers and methods to predict response to inhibitors and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-2904115-B1 | BIOMARKERS AND METHODS TO PREDICT RESPONSE TO INHIBITORS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2771489-B1 | BIOMARKERS OF RESPONSE TO NAE INHIBITORS | MILLENNIUM PHARM INC (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9920373-B2 | Biomarkers of response to proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-2776586-B1 | BIOMARKERS OF RESPONSE TO PROTEASOME INHIBITORS | MILLENNIUM PHARM INC (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2776043-B1 | BIOMARKERS OF RESPONSE TO PROTEASOME INHIBITORS | MILLENNIUM PHARM INC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170105995-A1 | BIOMARKERS OF RESPONSE TO NAE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20160312309-A1 | ASSESSMENT OF CHROMOSOMAL ALTERATIONS TO PREDICT CLINICAL OUTCOME OF BORTEZOMIB TREATMENT | MILLENNIUM PHARMACEUTICALS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20150240315-A1 | BIOMARKERS AND METHODS TO PREDICT RESPONSE TO INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150152502-A1 | BIOMARKERS OF RESPONSE TO PROTEASOME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20100086922-A1 | Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| EP-2046973-A2 | FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH CANCER THERAPY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008021183-A9 | FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH CANCER THERAPY | MILLENNIUM PHARM INC (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008021183-A2 | FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH CANCER THERAPY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152502-A1 | BIOMARKERS OF RESPONSE TO PROTEASOME INHIBITORS | PSMB4, PSMB1, PSME3 | MMP2 2441/4885MMP9 3831/4885MMP8 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.